DUCHENNE NOW Competitors

If you’re seeking to start or advance your career with a purpose, Muscular Dystrophy Association is an employer that will enable you to thrive. The Muscular Dystrophy Association is the #1 voluntary health organization in the United States for people living with muscular dystrophy, ALS, and related neuromuscular diseases. For over 70 years, MDA has led the way in accelerating research, advancing care, and advocating for the support of our families. Our mission is to empower the people we serve to live longer, more independent lives. #MDA #MuscularDystrophy #ALS #neuromuscuar. Apply now.

Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com. Solid is headquartered in Charlestown, MA, USA.

CureDuchenne is the global leader in Duchenne research, patient care and innovation. We are committed to improving the lives of those affected by Duchenne through accelerating research, improving care and empowering the community. We won't stop until everyone has a cure. cureduchenne.org Founded by Paul and Debra Miller in 2003, after their son was diagnosed with the disease, CureDuchenne combines fundraising and venture philanthropy leveraging donor dollars to maximize support for promising research into effective treatments for those suffering from Duchenne. With transparency as a core value, investment proceeds are redeployed to support research and other mission critical programs to find a cure.